Xenon Pharmaceuticals financials
$37.25+1.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | 100.0% | — | — | — | — | — | — |
| Operating income | -$123.2M | -$112.3M | -$109.8M | -$96.3M | -$94.2M | -$72.7M | -$77.5M | -$73.7M | -$69.1M | -$59.0M | -$53.7M | -$55.7M |
| Net income | -$110.7M | -$102.3M | -$105.3M | -$90.9M | -$84.7M | -$65.0M | -$65.7M | -$62.8M | -$57.9M | -$47.9M | -$44.7M | -$48.5M |
| Net margin | — | — | — | — | — | −867.3% | — | — | — | — | — | — |
| Diluted EPS | $-1.11 | $-1.17 | $-1.31 | $-1.15 | $-1.07 | $-0.83 | $-0.84 | $-0.81 | $-0.75 | $-0.62 | $-0.64 | $-0.73 |
| EBITDA | -$122.6M | -$111.7M | -$109.2M | -$95.7M | -$93.6M | -$72.1M | -$76.8M | -$73.0M | -$68.5M | -$58.5M | -$53.7M | -$54.0M |
| Operating cash flow | -$95.4M | -$88.9M | -$81.5M | -$71.8M | -$64.2M | -$61.7M | -$54.4M | -$49.7M | -$31.2M | -$46.2M | -$35.4M | -$48.1M |
| Free cash flow | -$95.7M | -$89.0M | -$81.8M | -$72.0M | -$64.4M | -$61.7M | -$55.2M | -$50.3M | -$32.7M | -$46.4M | -$35.5M | -$49.3M |
| Diluted shares | 99.6M | 87.3M | 80.1M | 79.2M | 79.0M | 78.7M | 78.4M | 77.9M | 77.7M | 77.6M | 70.0M | 66.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $119.5M | $545.9M | $199.2M | $104.5M | $135.4M | $116.7M |
| Short-term investments | $811.2M | $548.9M | $349.7M | $357.8M | $352.2M | $433.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.30B | $1.39B | $633.2M | $607.8M | $674.3M | $743.3M |
| Total liabilities | $53.4M | $49.0M | $51.4M | $48.3M | $40.3M | $39.3M |
| Shareholders' equity | $1.24B | $1.34B | $581.8M | $559.5M | $634.0M | $704.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology